Fig. 3

Chinese glioma genome atlas proved the evidence of the importance of LTBP1 on glioma. a Histogram presented the expression of LTBP1 were significantly higher in WHO IV (blue) than WHO III (green) and WHO II (red); ****P<0.0001. b–c The expression of LTBP1 is significantly higher in recurrent than primary gliomas in all WHO classifications. In more detail, there are significant difference of LTBP1 expression between recurrent and primary WHO IV glioma, namely GBM. No significantly difference of LTBP1 expression were observed between recurrent and primary WHO II and III gliomas. **P<0.01; ns, not significantly different. d–e The expression of LTBP1 is significantly higher in IDH-wildtype than IDH-mutant gliomas of all WHO classifications. In detail, there are significant expression difference of LTBP1between IDH-wildtype and IDH-mutant WHO IV glioma, namely GBM. No significantly difference of LTBP1 expression were observed between IDH-wildtype and IDH-mutant in WHO II and III gliomas. ****P< 0.0001; ns, not significantly different. f–g The expression of LTBP1 is significantly higher in 1p/19q Non-codeletion than 1p/19q codeletion gliomas of all WHO classifications. In detail, there are significant difference of LTBP1 expression between 1p/19q Non-codeletion and 1p/19q codeletion WHO III-IV gliomas, namely GBM. No significantly difference of LTBP1 expression were observed between 1p/19q Non-codeletion and 1p/19q codeletion in WHO II gliomas. ****P < 0.0001; ns, not significantly different. h Kaplan–Meier analysis showed that significantly worse outcome of GBM were observed in high LTBP1 expression group than low LTBP1 expression group for both primary and recurrent gliomas. Log-rank (Mantel-Cox) test was used as statistical method. P<0.0001 in primary gliomas; P = 0.00016 in recurrent gliomas